| 摘要 |
Polyepitopic fragments (I) from the E6 and E7 proteins of human papilloma virus (HPV), are new. Polyepitopic fragments (I) from the E6 and E7 proteins of human papilloma virus (HPV), are new. (I) is contained within any of the sequences: ArgProArgLysLeuProGlnLeuCysThrGluLeuGlnThrThrIleHisAspIleIleLeu- GluCysValTyrCysLysGlnGlnLeu; ArgArgGluValTyrAspPheAlaPheArgAspLeuCysIleValTyrArgAspGlyAsn- ProTyr; IleSerGluTyrArgHisTyrCysTyrArgLeuTyrGlyThrThrLeuGluGlnGlnTyrAsn- LysProLeuCysAspLeuLeuIle; CysProGluGluLysGlnArgHisLeuAspLysLysGlnArgPheHisAsnIleArgGlyArg- Trp; GlyGlyAspThrProThrLeuHisGluTyrMetLeuAspLeuGlnProGluThrThrAspLeu- TyrCysTyrGlnAlaGluProAspArgAlaHisTyrAsnIleValThrPheCysCysLys; and LeuGlnAspLeuLeuMetGlyThrLeuGlyIleValCysProIleCysSerGlnLys. These represent, respectively, amino acids 15-44, 46-67, 80-108 or 118-139 of E6 or 2-25, 44-60 or 79-97 of E7, and bind stably to, respectively, the human leukocyte antigen (HLA) type molecules A2, A11, A29, B7, B8, B35, B44 or B51; A2, A3, A11, A24, A29, B7, B27, B35, B44 or B51; A1, A3, A11, A24, A29, B7, B18, B35, B44 or B51; A24, B8, B18, B27, B35, B44 or B51; A1, A2, B18, B35, B44 or B62; A1, A3, A11, A29, B7, B18, B35, B44 or B51; or A2, A3, A11, A29 or B44. Alternatively, (I) comprises their derivatives which bind to the same HLA molecules as the parent compounds, formed by substitution, deletion and/or addition of one or more amino acids, modification of at least one peptide bond (particularly replacement by retro or retro-inverso bonds) and/or substitution of at least one amino acid by a non-proteinogenic amino acid. Independent claims are also included for the following: (1) nucleic acid (II) that encodes (I) or its derivatives; (2) mono- or poly-clonal antibodies (Ab) directed against (I) or its derivatives; and (3) pharmaceutical composition or vaccine containing at least one (I), or its derivative, (II) or Ab.
|
